{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:15:46Z","timestamp":1791353746108,"version":"4.3.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04559-x","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:31:23Z","timestamp":1771234283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["GLP-1 receptor agonists and smoking cessation: therapeutic promise beyond glycemia"],"prefix":"10.1007","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-4000-9287","authenticated-orcid":false,"given":"Gaurab","family":"Bhaduri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9524-1525","authenticated-orcid":false,"given":"Shatavisa","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriparna","family":"Karak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmoy","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"4559_CR1","volume-title":"WHO Report on the Global Tobacco Epidemic, 2023: Protect People from Tobacco Smoke","author":"World Health Organization","year":"2023","unstructured":"World Health Organization, WHO Report on the Global Tobacco Epidemic, 2023: Protect People from Tobacco Smoke (WHO, Geneva, 2023)"},{"key":"4559_CR2","doi-asserted-by":"publisher","first-page":"1179173X2513371","DOI":"10.1177\/1179173X251337114","volume":"18","author":"A Abbasi","year":"2025","unstructured":"A. Abbasi, A. Tajik, F. Sharifi, J. Moghri, M. Momken, Z. Khalse, M. Varmaghani, Estimating the direct medical costs of Smoking-Attributable Non-communicable diseases in Northeastern Iran from 2015 to 2023. Tob. Use Insights. 18, 1179173X251337114 (2025). https:\/\/doi.org\/10.1177\/1179173X251337114","journal-title":"Tob. Use Insights"},{"key":"4559_CR3","doi-asserted-by":"publisher","first-page":"e2021043","DOI":"10.4178\/epih.e2021043","volume":"43","author":"SE Lee","year":"2021","unstructured":"S.E. Lee, C.W. Kim, H.B. Im, M. Jang, Patterns and predictors of smoking relapse among inpatient smoking intervention participants: a 1-year follow-up study in Korea. Epidemiol. Health. 43, e2021043 (2021). https:\/\/doi.org\/10.4178\/epih.e2021043","journal-title":"Epidemiol. Health"},{"issue":"5","key":"4559_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40292-020-00396-9","volume":"27","author":"F Giulietti","year":"2020","unstructured":"F. Giulietti, A. Filipponi, G. Rosettani, P. Giordano, C. Iacoacci, F. Spannella, R. Sarzani, Pharmacological approach to smoking cessation: an updated review for daily clinical practice. High. Blood Press. Cardiovasc. Prev. 27(5), 349\u2013362 (2020). https:\/\/doi.org\/10.1007\/s40292-020-00396-9","journal-title":"High. Blood Press. Cardiovasc. Prev."},{"issue":"1","key":"4559_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/clpt.2011.105","volume":"90","author":"J Audrain-McGovern","year":"2011","unstructured":"J. Audrain-McGovern, N.L. Benowitz, Cigarette smoking, nicotine, and body weight. Clin. Pharmacol. Ther. 90(1), 164\u2013168 (2011). https:\/\/doi.org\/10.1038\/clpt.2011.105","journal-title":"Clin. Pharmacol. Ther."},{"key":"4559_CR6","unstructured":"L. Collins, R.A. Costello, Glucagon-Like Peptide-1 Receptor Agonists. [Updated 2024 Feb 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/"},{"issue":"1","key":"4559_CR7","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","volume":"20","author":"EZ Fisman","year":"2021","unstructured":"E.Z. Fisman, A. Tenenbaum, The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc. Diabetol. 20(1), 225 (2021). https:\/\/doi.org\/10.1186\/s12933-021-01412-5","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"4559_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","volume":"179","author":"MK Klausen","year":"2022","unstructured":"M.K. Klausen, M. Thomsen, G. Wortwein, A. Fink-Jensen, The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. Br. J. Pharmacol. 179(4), 625\u2013641 (2022). https:\/\/doi.org\/10.1111\/bph.15677","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"4559_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1124\/pharmrev.121.000299","volume":"74","author":"L Wills","year":"2022","unstructured":"L. Wills, J.L. Ables, K.M. Braunscheidel, S.P.B. Caligiuri, K.S. Elayouby, C. Fillinger, M. Ishikawa, J.K. Moen, P.J. Kenny, Neurobiological mechanisms of nicotine reward and aversion. Pharmacol. Rev. 74(1), 271\u2013310 (2022). https:\/\/doi.org\/10.1124\/pharmrev.121.000299","journal-title":"Pharmacol. Rev."},{"key":"4559_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.neubiorev.2020.06.006","volume":"116","author":"TA Green","year":"2020","unstructured":"T.A. Green, M.T. Bardo, Opposite regulation of conditioned place preference and intravenous drug self-administration in rodent models: motivational and non-motivational examples. Neurosci. Biobehav Rev. 116, 89\u201398 (2020). https:\/\/doi.org\/10.1016\/j.neubiorev.2020.06.006","journal-title":"Neurosci. Biobehav Rev."},{"issue":"20","key":"4559_CR11","doi-asserted-by":"publisher","first-page":"13222","DOI":"10.3390\/ijerph192013222","volume":"19","author":"S Driva","year":"2022","unstructured":"S. Driva, A. Korkontzelou, S. Tonstad, N. Tentolouris, P. Katsaounou, The effect of smoking cessation on body weight and other metabolic parameters with focus on people with type 2 diabetes mellitus. Int. J. Environ. Res. Public. Health. 19(20), 13222 (2022). https:\/\/doi.org\/10.3390\/ijerph192013222","journal-title":"Int. J. Environ. Res. Public. Health"},{"issue":"10","key":"4559_CR12","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","volume":"23","author":"L Yammine","year":"2021","unstructured":"L. Yammine, C.E. Green, T.R. Kosten, de C. Dios, R. Suchting, S.D. Lane, C.D. Verrico, J.M. Schmitz, Exenatide adjunct to nicotine patch facilitates smoking cessation and May reduce Post-Cessation weight gain: A pilot randomized controlled trial. Nicotine Tob. Res. 23(10), 1682\u20131690 (2021). https:\/\/doi.org\/10.1093\/ntr\/ntab066","journal-title":"Nicotine Tob. Res."},{"key":"4559_CR13","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.eclinm.2024.102429","volume":"68","author":"H L\u00fcthi","year":"2024","unstructured":"H. L\u00fcthi, S. Lengsfeld, T. Burkard, A. Meienberg, N. Jeanloz, T. Vukajlovic, K. Bologna, M. Steinmetz, C. Bathelt, C.O. Sailer, M. Laager, D.R. Vogt, L.G. Hemkens, B. Speich, S.A. Urwyler, J. K\u00fchne, F. Baur, L.N. Lutz, T.E. Erlanger, M. Christ-Crain, B. Winzeler, Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 68, 102429 (2024). https:\/\/doi.org\/10.1016\/j.eclinm.2024.102429","journal-title":"EClinicalMedicine"},{"key":"4559_CR14","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.1016\/j.eclinm.2023.101865","volume":"57","author":"S Lengsfeld","year":"2023","unstructured":"S. Lengsfeld, T. Burkard, A. Meienberg, N. Jeanloz, T. Vukajlovic, K. Bologna, M. Steinmetz, C. Bathelt, C.O. Sailer, D.R. Vogt, L.G. Hemkens, B. Speich, S.A. Urwyler, J. K\u00fchne, F. Baur, L.N. Lutz, T.E. Erlanger, M. Christ-Crain, B. Winzeler, Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine. 57, 101865 (2023). https:\/\/doi.org\/10.1016\/j.eclinm.2023.101865","journal-title":"EClinicalMedicine"},{"issue":"8","key":"4559_CR15","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/M23-2718","volume":"177","author":"W Wang","year":"2024","unstructured":"W. Wang, N.D. Volkow, N.A. Berger, P.B. Davis, D.C. Kaelber, R. Xu, Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using Real-World data. Ann. Intern. Med. 177(8), 1016\u20131027 (2024). https:\/\/doi.org\/10.7326\/M23-2718","journal-title":"Ann. Intern. Med."},{"key":"4559_CR16","doi-asserted-by":"publisher","first-page":"102782","DOI":"10.1016\/j.eclinm.2024.102782","volume":"30","author":"N Alfaris","year":"2024","unstructured":"N. Alfaris, S. Waldrop, V. Johnson, B. Boaventura, K. Kendrick, F.C. Stanford, GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 30, 75:102782 (2024). https:\/\/doi.org\/10.1016\/j.eclinm.2024.102782","journal-title":"EClinicalMedicine"},{"issue":"1","key":"4559_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12991-024-00527-9","volume":"23","author":"S Lee","year":"2024","unstructured":"S. Lee, M. Li, G.H. Le, K.M. Teopiz, M. Vinberg, R. Ho, H.C.T. Au, S. Wong, K. Valentino, A.T.H. Kwan, J.D. Rosenblat, R.S. McIntyre, Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review. Ann. Gen. Psychiatry. 23(1), 45 (2024). https:\/\/doi.org\/10.1186\/s12991-024-00527-9","journal-title":"Ann. Gen. Psychiatry"},{"key":"4559_CR18","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 372, n71 (2021). https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"4559_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"J.A.C. Sterne, J. Savovi\u0107, M.J. Page, R.G. Elbers, N.S. Blencowe, I. Boutron, C.J. Cates, H.Y. Cheng, M.S. Corbett, S.M. Eldridge, J.R. Emberson, M.A. Hern\u00e1n, S. Hopewell, A. Hr\u00f3bjartsson, D.R. Junqueira, P. J\u00fcni, J.J. Kirkham, T. Lasserson, T. Li, A. McAleenan, B.C. Reeves, S. Shepperd, I. Shrier, L.A. Stewart, K. Tilling, I.R. White, P.F. Whiting, J.P.T. Higgins, RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 366, l4898 (2019). https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4559_CR20","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"J.A. Sterne, M.A. Hern\u00e1n, B.C. Reeves, J. Savovi\u0107, N.D. Berkman, M. Viswanathan, D. Henry, D.G. Altman, M.T. Ansari, I. Boutron, J.R. Carpenter, A.W. Chan, R. Churchill, J.J. Deeks, A. Hr\u00f3bjartsson, J. Kirkham, P. J\u00fcni, Y.K. Loke, T.D. Pigott, C.R. Ramsay, D. Regidor, H.R. Rothstein, L. Sandhu, P.L. Santaguida, H.J. Sch\u00fcnemann, B. Shea, I. Shrier, P. Tugwell, L. Turner, J.C. Valentine, H. Waddington, E. Waters, G.A. Wells, P.F. Whiting, J.P. Higgins, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 355, i4919 (2016). https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"1","key":"4559_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"C.R. Hooijmans, M.M. Rovers, de R.B. Vries, M. Leenaars, M. Ritskes-Hoitinga, M.W. Langendam, SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol. 14(1), 43 (2014). https:\/\/doi.org\/10.1186\/1471-2288-14-43","journal-title":"BMC Med. Res. Methodol."},{"issue":"7650","key":"4559_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"G.H. Guyatt, A.D. Oxman, G.E. Vist, R. Kunz, Y. Falck-Ytter, P. Alonso-Coello, H.J. Sch\u00fcnemann, GRADE Working Group, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 336(7650), 924\u2013926 (2008). https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"10","key":"4559_CR23","doi-asserted-by":"publisher","first-page":"e77284","DOI":"10.1371\/journal.pone.0077284","volume":"8","author":"E Egecioglu","year":"2013","unstructured":"E. Egecioglu, J.A. Engel, E. Jerlhag, The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 8(10), e77284 (2013). https:\/\/doi.org\/10.1371\/journal.pone.0077284","journal-title":"PLoS One"},{"issue":"5","key":"4559_CR24","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nn.4540","volume":"20","author":"LM Tuesta","year":"2017","unstructured":"L.M. Tuesta, Z. Chen, A. Duncan, C.D. Fowler, M. Ishikawa, B.R. Lee, X.A. Liu, Q. Lu, M. Cameron, M.R. Hayes, T.M. Kamenecka, M. Pletcher, P.J. Kenny, GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat. Neurosci. 20(5), 708\u2013716 (2017). https:\/\/doi.org\/10.1038\/nn.4540","journal-title":"Nat. Neurosci."},{"issue":"6","key":"4559_CR25","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","volume":"240","author":"RJ Herman","year":"2023","unstructured":"R.J. Herman, M.R. Hayes, J. Audrain-McGovern, R.L. Ashare, H.D. Schmidt, Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats. Psychopharmacol. (Berl). 240(6), 1373\u20131386 (2023). https:\/\/doi.org\/10.1007\/s00213-023-06376-w","journal-title":"Psychopharmacol. (Berl)"},{"issue":"5","key":"4559_CR26","doi-asserted-by":"publisher","first-page":"112466","DOI":"10.1016\/j.celrep.2023.112466","volume":"42","author":"S Falk","year":"2023","unstructured":"S. Falk, J. Petersen, C. Svendsen, C.R. Romero-Leguizam\u00f3n, S.H. J\u00f8rgensen, N. Krauth, M.Q. Ludwig, K. Lund\u00f8, U. Roostalu, G. Skovbjerg, D.A.G. Nielsen, A.L. Ejdrup, T.H. Pers, O. Dmytriyeva, J. Hecksher-S\u00f8rensen, U. Gether, K.A. Kohlmeier, C. Clemmensen, GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity. Cell. Rep. 42(5), 112466 (2023). https:\/\/doi.org\/10.1016\/j.celrep.2023.112466","journal-title":"Cell. Rep."},{"key":"4559_CR27","unstructured":"ClinicalTrials.gov, Daily Liraglutide for Nicotine Dependence (DAL). Accessed from https:\/\/clinicaltrials.gov\/study\/NCT03712098. Accessed on July 20, 2025"},{"key":"4559_CR28","unstructured":"ClinicalTrials.gov, Effects of Semaglutide on Nicotine Intake. Accessed from https:\/\/clinicaltrials.gov\/study\/NCT05530577. Accessed on July 20, 2025"},{"key":"4559_CR29","unstructured":"ClinicalTrials.gov, Exenatide for Smoking Cessation and Prevention of Weight Gain. Accessed from https:\/\/clinicaltrials.gov\/study\/NCT05610800. Accessed on July 20, 2025"},{"key":"4559_CR30","unstructured":"ClinicalTrials.gov, Semaglutide for Post-Smoking Cessation Weight Management. Accessed from https:\/\/clinicaltrials.gov\/study\/NCT06173778. Accessed on July 20, 2025"},{"issue":"2","key":"4559_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S2213-8587(19)30423-1","volume":"8","author":"HC Gerstein","year":"2020","unstructured":"H.C. Gerstein, R. Hart, H.M. Colhoun, R. Diaz, M. Lakshmanan, F.T. Botros, J. Probstfield, M.C. Riddle, L. Ryd\u00e9n, C.M. Atisso, L. Dyal, S. Hall, A. Avezum, J. Basile, I. Conget, W.C. Cushman, N. Hancu, M. Hanefeld, P. Jansky, M. Keltai, F. Lanas, L.A. Leiter, P. Lopez-Jaramillo, E.G.C. Mu\u00f1oz, N. Pogosova, P.J. Raubenheimer, J.E. Shaw, W.H. Sheu, T. Temelkova-Kurktschiev, The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 8(2), 106\u2013114 (2020). https:\/\/doi.org\/10.1016\/S2213-8587(19)30423-1","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"4559_CR32","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.14890","volume":"25","author":"MN Kosiborod","year":"2023","unstructured":"M.N. Kosiborod, M. Bhatta, M. Davies, J.E. Deanfield, W.T. Garvey, U. Khalid, R. Kushner, D.M. Rubino, N. Zeuthen, S. Verma, Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes. Metab. 25(2), 468\u2013478 (2023). https:\/\/doi.org\/10.1111\/dom.14890","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"4559_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/adb.12295","volume":"21","author":"D Vall\u00f6f","year":"2016","unstructured":"D. Vall\u00f6f, P. Maccioni, G. Colombo, M. Mandrapa, J.W. J\u00f6rnulf, E. Egecioglu, J.A. Engel, E. Jerlhag, The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict. Biol. 21(2), 422\u2013437 (2016). https:\/\/doi.org\/10.1111\/adb.12295","journal-title":"Addict. Biol."},{"key":"4559_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/DMSO.S387116","volume":"16","author":"M Aldawsari","year":"2023","unstructured":"M. Aldawsari, F.A. Almadani, N. Almuhammadi, S. Algabsani, Y. Alamro, M. Aldhwayan, The efficacy of GLP-1 analogues on appetite Parameters, gastric Emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials. Diabetes Metab. Syndr. Obes. 16, 575\u2013595 (2023). https:\/\/doi.org\/10.2147\/DMSO.S387116","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"2","key":"4559_CR35","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2337\/db13-1764","volume":"63","author":"J Tong","year":"2014","unstructured":"J. Tong, D. D\u2019Alessio, Give the receptor a brake: slowing gastric emptying by GLP-1. Diabetes. 63(2), 407\u2013409 (2014). https:\/\/doi.org\/10.2337\/db13-1764","journal-title":"Diabetes"},{"issue":"11","key":"4559_CR36","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.3390\/nu12113304","volume":"12","author":"Y Diz-Chaves","year":"2020","unstructured":"Y. Diz-Chaves, S. Herrera-P\u00e9rez, L.C. Gonz\u00e1lez-Mat\u00edas, J.A. Lamas, F. Mallo, Glucagon-Like Peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress. Nutrients. 12(11), 3304 (2020). https:\/\/doi.org\/10.3390\/nu12113304","journal-title":"Nutrients"},{"issue":"1","key":"4559_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.296.1.56","volume":"296","author":"D.E. Jorenby","year":"2006","unstructured":"D.E. Jorenby, J.T. Hays, N.A. Rigotti, S. Azoulay, E.J. Watsky, K.E. Williams, C.B. Billing, J. Gong, K.R. Reeves, Varenicline Phase 3 Study Group, Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296(1), 56\u201363 (2006) https:\/\/doi.org\/10.1001\/jama.296.1.56","journal-title":"JAMA"},{"issue":"6","key":"4559_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/pharmaceutics17060706","volume":"17","author":"L Ding","year":"2025","unstructured":"L. Ding, P. Kshirsagar, P. Agrawal, D.J. Murry, Crossing the Blood-Brain barrier: innovations in Receptor- and Transporter-Mediated transcytosis strategies. Pharmaceutics. 17(6), 706 (2025). https:\/\/doi.org\/10.3390\/pharmaceutics17060706","journal-title":"Pharmaceutics"},{"key":"4559_CR39","doi-asserted-by":"publisher","first-page":"114565","DOI":"10.1016\/j.physbeh.2024.114565","volume":"281","author":"RJ Herman","year":"2024","unstructured":"R.J. Herman, H.D. Schmidt, Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence. Physiol. Behav. 281, 114565 (2024). https:\/\/doi.org\/10.1016\/j.physbeh.2024.114565","journal-title":"Physiol. Behav."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04559-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04559-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T22:02:33Z","timestamp":1771279353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04559-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4559"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04559-x","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"82"}}